title: Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.
abstract: Cancer progression depends on stepwise accumulation of oncogenic mutations and a select group of growth factors essential for tumor growth, metastasis and angiogenesis. Agents blocking the epidermal growth factor receptor (EGFR, also called HER1 and ERBB1) and the co-receptor called HER2/ERBB2 have been approved over the last decade as anti-cancer drugs. Because the catalytically defective member of the family, HER3/ERBB3, plays critical roles in emergence of resistance of carcinomas to various drugs, current efforts focus on antibodies and other anti-HER3/ERBB3 agents, which we review herein with an emphasis on drug combinations and some unique biochemical features of HER3/ERBB3.
authors.affiliation: a Department of Biological Regulation , Weizmann Institute of Science , Rehovot , Israel.
authors.forename: Nadège
authors.initials: N
authors.lastname: Gaborit
authors.affiliation: a Department of Biological Regulation , Weizmann Institute of Science , Rehovot , Israel.
authors.forename: Moshit
authors.initials: M
authors.lastname: Lindzen
authors.affiliation: a Department of Biological Regulation , Weizmann Institute of Science , Rehovot , Israel.
authors.forename: Yosef
authors.initials: Y
authors.lastname: Yarden
mesh_terms: D000818:Animals; D000906:Antibodies / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D004351:Drug Resistance; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*; D020893:Receptor, ErbB-3 / Q000037:antagonists & inhibitors* / Q000276:immunology*
chemical_list: D000906:Antibodies; D000970:Antineoplastic Agents; C581292:ERBB3 protein, human; D020893:Receptor, ErbB-3
keywords: HER3/ERBB3; anti-cancer drugs; monoclonal antibodies; receptor tyrosine kinase; signal transduction